Rheumatoid Arthritis When Methotrexate Is Contraindicated or Not Tolerated

When methotrexate cannot be used due to a contraindication or early intolerance, and no poor prognostic factors are present, a specific first-line csDMARD strategy is indicated for rheumatoid arthritis.

Clinical Scenario

This protocol applies when all of the following conditions are met:

Treatment Approach

An alternative conventional synthetic DMARD forms the backbone of the first-line strategy, combined where appropriate with a short course of glucocorticoids as bridging support — with the full drug selection, dosing, and tapering schedule detailed in the protocol.

Clinical Goals

The target is at least 50% improvement in disease activity within 3 months, progressing to sustained remission or low disease activity by 6 months. If the target is not reached, therapy should be reassessed.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2022-223356 View source ↗